Caspar has made over 3 trades of the Cerus stock since 2015, according to the Form 4 filled with the SEC. Most recently Caspar exercised 50,000 units of CERS stock worth 178,000$ on 10 December 2015.
The largest trade Caspar's ever made was exercising 50,000 units of Cerus stock on 10 December 2015 worth over 178,000$. On average, Caspar trades about 15,000 units every 19 days since 2010.
You can see the complete history of Caspar Hogeboom stock trades at the bottom of the page.
Caspar's mailing address filed with the SEC is C/O CERUS CORPORATION, 2550 STANWELL DRIVE, CONCORD, CA, 94520.
Over the last 21 years, insiders at Cerus have traded over 5,083,598$ worth of Cerus stock and bought 1,382,745 units worth 4,903,526$ . The most active insiders traders include William Mariner Greenman、Laurence M Corash、Bruce C Cozadd. On average, Cerus executives and independent directors trade stock every 33 days with the average trade being worth of 90,805$. The most recent stock trade was executed by Kevin Dennis Green on 3 September 2024, trading 82,657 units of CERS stock currently worth 178,539$.
cerus corporation is a biomedical products company focused on commercializing the intercept blood system to enhance blood safety. the intercept system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. the nucleic acid targeting mechanism of action enables intercept treatment to inactivate established transfusion threats, such as hepatitis b and c, hiv, west nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. cerus currently markets and sells the intercept blood system for both platelets and plasma in europe, russia, the middle east and selected countries in other regions around the world. the intercept red blood cell system is in clinical development.
Cerus executives and other stock owners filed with the SEC include: